<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; offerings</title>
	<atom:link href="http://www.tapanray.in/tag/offerings/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Drug Pricing: Why Justify On R&amp;D Cost Rather Than Precise ‘Customer Value’?</title>
		<link>http://www.tapanray.in/drug-pricing-why-justify-on-rd-cost-rather-than-precise-customer-value/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=drug-pricing-why-justify-on-rd-cost-rather-than-precise-customer-value</link>
		<comments>http://www.tapanray.in/drug-pricing-why-justify-on-rd-cost-rather-than-precise-customer-value/#comments</comments>
		<pubDate>Mon, 16 Dec 2019 00:00:05 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[brand]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[connects]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[customer]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[eclectic]]></category>
		<category><![CDATA[electronics]]></category>
		<category><![CDATA[emotional]]></category>
		<category><![CDATA[expenditure]]></category>
		<category><![CDATA[focus]]></category>
		<category><![CDATA[high]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[justification]]></category>
		<category><![CDATA[justify]]></category>
		<category><![CDATA[lawsuit]]></category>
		<category><![CDATA[model]]></category>
		<category><![CDATA[monetary]]></category>
		<category><![CDATA[offerings]]></category>
		<category><![CDATA[Oregon]]></category>
		<category><![CDATA[prices]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[unique]]></category>
		<category><![CDATA[value]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9815</guid>
		<description><![CDATA[While looking around, it won’t be difficult to spot many types of steep-priced highly innovative products, where high costs aren’t justified by high R&#38;D expenditure, but for unique ‘customer value’ offerings. Many consumers evaluate those and decide to settle for &#8230; <a href="http://www.tapanray.in/drug-pricing-why-justify-on-rd-cost-rather-than-precise-customer-value/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/drug-pricing-why-justify-on-rd-cost-rather-than-precise-customer-value/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Changing &#8211; The Key Differentiator To Boost Pharma Market Share</title>
		<link>http://www.tapanray.in/changing-the-key-differentiator-to-boost-pharma-market-share/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=changing-the-key-differentiator-to-boost-pharma-market-share</link>
		<comments>http://www.tapanray.in/changing-the-key-differentiator-to-boost-pharma-market-share/#comments</comments>
		<pubDate>Mon, 08 Jul 2019 00:00:27 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Awards]]></category>
		<category><![CDATA[brand]]></category>
		<category><![CDATA[breathe of life]]></category>
		<category><![CDATA[Cannes]]></category>
		<category><![CDATA[changing]]></category>
		<category><![CDATA[communication]]></category>
		<category><![CDATA[creative]]></category>
		<category><![CDATA[differentiator]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Lions]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[offerings]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[problem]]></category>
		<category><![CDATA[Problem-solving]]></category>
		<category><![CDATA[process]]></category>
		<category><![CDATA[product-centric]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Share]]></category>
		<category><![CDATA[solution-centric]]></category>
		<category><![CDATA[solving]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Ways]]></category>
		<category><![CDATA[wellness]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9622</guid>
		<description><![CDATA[Health problems, affecting populations of any country, are many. So are the issues related to the delivery of effective health care solution, that most patients would consider satisfying and meaningful. From this perspective, prevention, treatment and effectively managing any disease &#8230; <a href="http://www.tapanray.in/changing-the-key-differentiator-to-boost-pharma-market-share/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/changing-the-key-differentiator-to-boost-pharma-market-share/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
